YH 1885

proton pump inhibitor; structure in first source

Also Known As:

5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine; Revaprazan; Revaprazan hydrochloride; YH-1885

Networked: 8 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - Pyrimidinones: 71
      - YH 1885: 8
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Isoquinolines: 34
      - Tetrahydroisoquinolines: 44
        YH 1885: 8

Experts

1.	Allen, Aurelia A: 1 article (12/2019)
2.	Peralta-Yahya, Pamela: 1 article (12/2019)
3.	Sugianto, Widianti: 1 article (12/2019)
4.	Yasi, Emily A: 1 article (12/2019)
5.	Ahn, Sang Bong: 1 article (09/2015)
6.	Jo, Young Kwan: 1 article (09/2015)
7.	Jo, Yunju: 1 article (09/2015)
8.	Kim, Hyo Jeong: 1 article (09/2015)
9.	Kim, Seong Hwan: 1 article (09/2015)
10.	Park, Eunkyoung: 1 article (09/2015)

Related Diseases

1.	Peptic Ulcer (Peptic Ulcers) 12/31/2023 - "Revaprazan (REV), a novel reversible Proton Pump Inhibitor (PPI) used to treat peptic ulcers, faces challenges in therapeutic efficacy due to its poor dissolution properties and a short half-life. " 01/01/2011 - "pylori) associated peptic ulcer disease who were treated with revaprazan and evaluate the anti-urease activity of revaprazan. " 01/01/2011 - "[Effect of acid pump antagonist (Revaprazan, Revanex(R)) on result of 13C urea breath test in patients with Helicobacter pylori associated peptic ulcer disease]." 01/01/2011 - "[Effect of acid pump antagonist (Revaprazan, Revanex(R)) on the result of 13C urea breath test in the patients with Helicobacter pylori associated peptic ulcer disease]."
2.	Infections 09/01/2012 - "pylori infection in the presence or absence of revaprazan. " 12/20/2019 - "We used the assay to screen more than 1000 natural products and anti-infection agents and identified five new 5-HTR4b ligands: hordenine, halofuginone, proflavine, ethacridine, and revaprazan. "
3.	Ulcer 03/01/2010 - "The safety and efficacy profiles of revaprazan and rabeprazole are similar for the treatment of ESD-induced ulcers." 03/01/2010 - "In the revaprazan group, only one patient had stage H2 disease: a 54-year-old man with a 5.5-cm lesion after ESD of the ulcer, type IIa early gastric cancer, and adenocarcinoma. " 03/01/2010 - "Revaprazan, a novel acid-pump antagonist, and proton-pump inhibitors (PPIs) have pH-independent effects on ulcer healing. "
4.	Stomach Ulcer (Gastric Ulcer) 09/23/2015 - "For 8 weeks, either a PPI or revaprazan was randomly assigned to patients with gastric ulcers. "
5.	Stomach Neoplasms (Stomach Cancer) 03/01/2010 - "In the revaprazan group, only one patient had stage H2 disease: a 54-year-old man with a 5.5-cm lesion after ESD of the ulcer, type IIa early gastric cancer, and adenocarcinoma. "

Related Drugs and Biologics

1.	Proton Pump Inhibitors
2.	Acids
3.	Urea (Carbamide)
4.	Rabeprazole (Aciphex)
5.	Lansoprazole (Prevacid)
6.	Urease
7.	Proflavine (Proflavin)
8.	Omeprazole (Prilosec)
9.	Ligands
10.	Ethacridine (Ethacridine Lactate)